Development of a Bivalent Conjugate Vaccine Candidate Against Malaria Transmission and Typhoid Fever

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2018 Apr 24

PMID 29681410

Citations 6

Authors

So Jung An

Puthupparampil V Scaria

Beth Chen

Emma Barnafo

Olga Muratova

Charles Anderson

Lynn Lambert

Myung Hwa Chae

Jae Seung Yang

Patrick E Duffy

Affiliations

Soon will be listed here.

Abstract

Immune responses to poorly immunogenic antigens, such as polysaccharides, can be enhanced by conjugation to carriers. Our previous studies indicate that conjugation to Vi polysaccharide of Salmonella Typhi may also enhance immunogenicity of some protein carriers. We therefore explored the possibility of generating a bivalent vaccine against Plasmodium falciparum malaria and typhoid fever, which are co-endemic in many parts of the world, by conjugating Vi polysaccharide, an approved antigen in typhoid vaccine, to Pfs25, a malaria transmission blocking vaccine antigen in clinical trials. Vi-Pfs25 conjugates induced strong immune responses against both Vi and Pfs25 in mice, whereas the unconjugated antigens are poorly immunogenic. Functional assays of immune sera revealed potent transmission blocking activity mediated by anti-Pfs25 antibody and serum bactericidal activity due to anti-Vi antibody. Pfs25 conjugation to Vi modified the IgG isotype distribution of antisera, inducing a Th2 polarized immune response against Vi antigen. This conjugate may be further developed as a bivalent vaccine to concurrently target malaria and typhoid fever.

Citing Articles

Carriers and Antigens: New Developments in Glycoconjugate Vaccines.

van der Put R, Metz B, Pieters R Vaccines (Basel). 2023; 11(2).

PMID: 36851097 PMC: 9962112. DOI: 10.3390/vaccines11020219.

Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques.

Scaria P, Anderson C, Muratova O, Alani N, Trinh H, Nadakal S NPJ Vaccines. 2021; 6(1):148.

PMID: 34887448 PMC: 8660773. DOI: 10.1038/s41541-021-00407-3.

Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine.

Park W, Yoon Y, Park J, Pansuriya R, Seok Y, Ganapathy R Sci Rep. 2021; 11(1):22037.

PMID: 34764353 PMC: 8586335. DOI: 10.1038/s41598-021-01549-z.

Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved Th1-Type Cytokine Recall Responses in Human Whole Blood.

Adeagbo B, Akinlalu A, Phan T, Guderian J, Boukes G, Willenburg E ACS Omega. 2020; 5(48):31306-31313.

PMID: 33324841 PMC: 7726955. DOI: 10.1021/acsomega.0c04774.

Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.

Scaria P, Chen B, Rowe C, Alani N, Muratova O, Barnafo E Vaccine. 2020; 38(34):5480-5489.

PMID: 32600913 PMC: 11127250. DOI: 10.1016/j.vaccine.2020.06.018.

References

Rowe A, Rowe S, Snow R, Korenromp E, Schellenberg J, Stein C . The burden of malaria mortality among African children in the year 2000. Int J Epidemiol. 2006; 35(3):691-704. PMC: 3672849. DOI: 10.1093/ije/dyl027. View

Gething P, Patil A, Smith D, Guerra C, Elyazar I, Johnston G . A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011; 10:378. PMC: 3274487. DOI: 10.1186/1475-2875-10-378. View

Miura K, Orcutt A, Muratova O, Miller L, Saul A, Long C . Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine. 2007; 26(2):193-200. PMC: 2253722. DOI: 10.1016/j.vaccine.2007.10.064. View

Vidarsson G, Dekkers G, Rispens T . IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014; 5:520. PMC: 4202688. DOI: 10.3389/fimmu.2014.00520. View

Uneke C . Concurrent malaria and typhoid fever in the tropics: the diagnostic challenges and public health implications. J Vector Borne Dis. 2008; 45(2):133-42. View

Kothari N, Kothari S, Choi Y, Dey A, Briles D, Rhee D . A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi. Vaccine. 2014; 33(6):783-8. DOI: 10.1016/j.vaccine.2014.12.032. View

Jang H, Yoon Y, Kim J, Kim H, An S, Seo J . Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor. J Biotechnol. 2008; 135(1):71-7. DOI: 10.1016/j.jbiotec.2008.02.017. View

An S, Woo J, Chae M, Kothari S, Carbis R . Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine. Vaccine. 2015; 33(13):1614-9. DOI: 10.1016/j.vaccine.2015.01.061. View

Ferrante A, Beard L, Feldman R . IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J. 1990; 9(8 Suppl):S16-24. View

10.

Mogasale V, Maskery B, Ochiai R, Lee J, Mogasale V, Ramani E . Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014; 2(10):e570-80. DOI: 10.1016/S2214-109X(14)70301-8. View

11.

Crump J . Typhoid Fever and the challenge of nonmalaria febrile illness in sub-saharan Africa. Clin Infect Dis. 2012; 54(8):1107-9. DOI: 10.1093/cid/cis024. View

12.

Tsai C, Duggan P, Shimp Jr R, Miller L, Narum D . Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J Biotechnol. 2005; 121(4):458-70. DOI: 10.1016/j.jbiotec.2005.08.025. View

13.

Kossaczka Z, Bystricky S, Bryla D, Shiloach J, Robbins J, Szu S . Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun. 1997; 65(6):2088-93. PMC: 175288. DOI: 10.1128/iai.65.6.2088-2093.1997. View

14.

Radtke A, Anderson C, Riteau N, Rausch K, Scaria P, Kelnhofer E . Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Sci Rep. 2017; 7:40312. PMC: 5238395. DOI: 10.1038/srep40312. View

15.

Kumar R, Ray P, Datta D, Bansal G, Angov E, Kumar N . Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine. 2015; 33(39):5064-71. PMC: 4577455. DOI: 10.1016/j.vaccine.2015.08.025. View

16.

. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386(9988):31-45. PMC: 5626001. DOI: 10.1016/S0140-6736(15)60721-8. View

17.

Avci F, Li X, Tsuji M, Kasper D . A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med. 2011; 17(12):1602-9. PMC: 3482454. DOI: 10.1038/nm.2535. View

18.

Szu S . Development of Vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines. 2013; 12(11):1273-86. DOI: 10.1586/14760584.2013.845529. View

19.

STEIN K . Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992; 165 Suppl 1:S49-52. DOI: 10.1093/infdis/165-supplement_1-s49. View

20.

Broker M, Berti F, Schneider J, Vojtek I . Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations. Vaccine. 2017; 35(25):3286-3294. DOI: 10.1016/j.vaccine.2017.04.078. View